In fact, significant progress has been made since the approval by the U.S. Food and Drug Administration (FDA) of the first monoclonal antibody (mAb)-based, prostate specific membrane antigen (PSMA)-targeted radioligand—ProstaScint® (Indium-111 Capromab Pendetide)—for SPECT imaging of PCa [3,4,5,6,7,8], back in 1996. Here, FOLH1 is linked to posterior cortical atrophy.